Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash provided by (used for) operating activities
Cash provided by (used for) operating activities	$ 835	$ 1,144
Investing activities:
Purchases of property, plant and equipment	(217)	(275)
Proceeds from sale of property, plant and equipment	6	5
Payments for acquisitions of businesses, net of cash acquired	(3)	(4,382)
Proceeds from royalty rights	66	0
Payments for investments and acquisitions of certain technologies	(130)	(137)
Proceeds from divestiture	15	90
Payments for settlements of hedge contracts	0	(294)
Cash provided by (used for) investing activities	(264)	(4,992)
Financing activities:
Payment of contingent consideration and royalty rights established in purchase accounting	(132)	(135)
Payments on short-term borrowings	(2,950)	(1,000)
Proceeds from short-term borrowings, net of debt issuance costs	2,245	0
Net increase (decrease) in commercial paper	(714)	13
Payments on borrowings from credit facilities	(1,919)	0
Proceeds from borrowings on credit facilities	1,916	0
Payments on long-term borrowings and debt extinguishment costs	(1,000)	(1,472)
Proceeds from long-term borrowings, net of debt issuance costs	1,683	6,243
Cash dividends paid on preferred stock	(14)	0
Net proceeds from issuance of preferred stock in connection with public offering	975	0
Net proceeds from issuance of common stock in connection with public offering	975	0
Cash used to net share settle employee equity awards	(59)	(64)
Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans	107	113
Cash provided by (used for) financing activities	1,112	3,697
Effect of foreign exchange rates on cash	(8)	(2)
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents	1,675	(153)
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period	607	829
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period	2,282	676
Supplemental Information
Stock-based compensation expense	128	116
Fair value of contingent consideration recorded in purchase accounting	0	127
Non-cash impact of transferred royalty rights	$ (66)	$ 0